Immutep (IMMP) has released an update.
Immutep Limited has secured an exclusive license agreement with Cardiff University for the development and commercialization of a new class of anti-LAG-3 molecules aimed at treating cancer. These small molecule compounds, which can be administered orally, show potential to enhance the immune response against cancer at a lower cost than current antibody treatments. The deal includes an upfront payment, milestone payments, and sales royalties for Cardiff University, strengthening Immutep’s position in immunotherapy.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
